Overview Information

Department of Health and Human Services

Participating Organization(s)
National Institutes of Health (NIH), (http://www.nih.gov)

Components of Participating Organizations
National Heart, Lung, and Blood Institute (NHLBI), (http://www.nhlbi.nih.gov)

Title: NHLBI Progenitor Cell Translational Consortium (U01)

Activity Code: U01 Research Project – Cooperative Agreements

Announcement Type: New

Related Notices

  • December 16, 2015 - Notice of New Application Forms Package for RFA-HL-16-021. See Notice NOT-HL-15-291.
  • NOT-OD-16-004 - NIH & AHRQ Announce Upcoming Changes to Policies, Instructions and Forms for 2016 Grant Applications (November 18, 2015)
  • NOT-OD-16-006 - Simplification of the Vertebrate Animals Section of NIH Grant Applications and Contract Proposals (November 18, 2015)
  • NOT-OD-16-011 - Implementing Rigor and Transparency in NIH & AHRQ Research Grant Applications (November 18, 2015)

Funding Opportunity Announcement (FOA) Number: RFA-HL-16-021

Companion Funding Opportunity

RFA-HL-16-022U24 Resource-Related Research Projects--Cooperative Agreements

Number of Applications

See Section III. 3. Additional Information on Eligibility.

Catalog of Federal Domestic Assistance (CFDA) Number(s)

93.837, 93.838, 93.839

Funding Opportunity Purpose

This Funding Opportunity Announcement requests applications to participate in the NHLBI Progenitor Cell Translational Consortium (PCTC). The goal of the Consortium is to translate advances in progenitor cell biology towards application to heart, lung, and blood diseases. The initiative will focus on the use of progenitor cell-based disease models to understand disease mechanisms, the development of novel therapies, and the application of cell-based therapies for the treatment of diseases.

Key Dates

  • Posted Date: November 10, 2015
  • Open Date (Earliest Submission Date): January 8, 2016
  • Letter of Intent Due Date(s): January 8, 2016
  • Application Due Date(s): February 8, 2016, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.  Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  • Scientific Merit Review: June 2016
  • Advisory Council Review: August 2016
  • Earliest Start Date: September 2016
  • Expiration Date: February 9, 2016

Due Dates for E.O. 12372: Not Applicable

Required Application Instructions

It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide, except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts). Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.


Copyright ©2016 NHLBI Progenitor Cell Translational Consortium.

University of Maryland School of Medicine logo

National Heart Blood and Lung Institute logo